39 results
8-K
VERV
Verve Therapeutics Inc
2 Apr 24
Other Events
7:13am
”) by the U.K. Medicines and Healthcare products Regulatory Agency (“MHRA”) and Health Canada for VERVE-102, with the Heart-2 Phase 1b clinical trial
8-K
EX-1.1
67pnoa ycs9eccpr
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
424B5
pe4bgkz7
29 Nov 23
Prospectus supplement for primary offering
4:47pm
424B5
qu9xgsrhuvl56zd
28 Nov 23
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
ep3s694pgb
7 Nov 23
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
2fx876nvy
15 May 23
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
7:00am
S-3ASR
tw6ls7vc3i ly8l3wink
23 Sep 22
Automatic shelf registration
4:08pm